ArticleFrontiers in pharmacology2017
Quantum Dots-siRNA Nanoplexes for Gene Silencing in Central Nervous System Tumor Cells.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 56 citations in OpenAlex.
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Quantum Dots in Cancer Theranostics: A Thorough Review of Recent Advancements in Bioimaging, Tracking, and Therapy Across Various Cancer Types.Current pharmaceutical biotechnology · 2025Review
- Advances and Challenges in Nano-Delivery Systems for Glioblastoma Treatment: A Comprehensive Review.International journal of nanomedicine · 2025Review
- Recent advances in gene delivery nanoplatforms based on spherical nucleic acids.Journal of nanobiotechnology · 2024Review
- Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.Molecular neurobiology · 2024Review
- Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment.Asian journal of pharmaceutical sciences · 2023Review
- Challenges and advances for glioma therapy based on inorganic nanoparticles.Materials today. Bio · 2023Review
- CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia.Cell proliferation · 2022Article
- Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Cyclic Peptide-Gadolinium Nanocomplexes as siRNA Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Quantum dots in biomedical applications.Acta biomaterialia · 2019Review
- Review
- The Codelivery of siRNA and QDs by pH-Responsive Micelle for Hepatoma Cancer Cells.Frontiers in pharmacology · 2019Article
- Article
- Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interfering (RNAi) using short interfering RNA (siRNA) is becoming a promising approach for cancer gene therapy. However, owing to the lack of safe and efficient carriers, the application of RNAi for clinical use is still very limited. In this study, we have developed cadmium sulphoselenide/Zinc sulfide quantum dots (CdSSe/ZnS QDs)-based nanocarriers for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.